Ultragenyx Pharmaceutical
RARE
RARE
161 hedge funds and large institutions have $1.81B invested in Ultragenyx Pharmaceutical in 2016 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 60 increasing their positions, 59 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
161
Holders Change
–
Holders Change %
0%
% of All Funds
4.3%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
22
Increased
60
Reduced
59
Closed
21
Calls
$5.47M
Puts
$6.35M
Net Calls
-$876K
Net Calls Change
+$403K
Top Buyers
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$13.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.9M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$8.87M |
| 4 |
Millennium Management
New York
|
+$8.58M |
| 5 |
Goldman Sachs
New York
|
+$8.01M |
Top Sellers
| 1 |
VAM
Visium Asset Management
New York
|
-$33.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$24.1M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
-$19.1M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$18.6M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$6.58M |
